A Retrospective Study on the Effect of Chinese Patent Medicine Combined with Conventional Treatment on the Survival Outcomes of 313 Patients with Stage II-III NSCLC

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 Mar 31

PMID 38555532

Authors

Kegang Jia

Chenxu Zhang

Fang Li

Bin He

Shenglong Xie

Jun Du

Gang Feng

Affiliations

Soon will be listed here.

Abstract

Purpose: We aim to explore the effect of Chinese Patent Medicine (CPM), including Huisheng oral solution (HSOS) on the 4-year survival rate of patients with stage II and III non-small cell lung cancer, and assess the association between blood coagulation indicators and survival outcomes.

Materials And Methods: 313 patients diagnosed with stage II and III NSCLC were collected during 2015-2016. Kaplan-Meier method and Cox proportional hazard model were applied to analyze the factors affecting the 4-year survival rate of patients.

Results: According to the effect of CPM, the medicine prescribed in this study could be classified into two types. The proportion of patients who received "Fuzheng Quyu" CPM for more than three months was higher than the proportion of patients who received other two types of CPM for more than three months. Medical records of 313 patients with NSCLC were analyzed. 4-year survival rate for patients received CPM more than 6 months and 3 months were higher than those received CPM less than 3 months ( = 0.028 and = 0.021 respectively. In addition, 4-year survival rate for patients who received HSOS for more than 3 months was higher than those who received HSOS for less than 3 months ( = 0.041). Patients with elevated preoperative fibrinogen (FIB) level and those without surgery had an increased mortality risk (HR = 1.98, < 0.01, and HR = 2.76, < 0.01 respectively).

Conclusion: The medium and long-term use of CPM/HSOS was positively associated with higher survival rate in NSCLC patients. Patients with high-level preoperative FIB level and those without surgery might have a poor prognosis in the following years.

References

Chen Z, Sun D, Bi X, Zeng X, Luo W, Cai D . Pharmacokinetic based study on "lagged stimulation" of Curcumae Longae Rhizoma - Piper nigrum couplet in their main active components' metabolism using UPLC-MS-MS. Phytomedicine. 2017; 27:15-22. DOI: 10.1016/j.phymed.2017.01.012. View

Wang X, Yu R, Wang Y . [Study on advanced non-small cell lung cancer patients with Qi deficiency and blood stasis syndrome]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1994; 14(12):724-6. View

Cedervall J, Hamidi A, Olsson A . Platelets, NETs and cancer. Thromb Res. 2018; 164 Suppl 1:S148-S152. DOI: 10.1016/j.thromres.2018.01.049. View

Lin Y, Liu Z, Qiu Y, Zhang J, Wu H, Liang R . Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2018; 44(10):1494-1503. DOI: 10.1016/j.ejso.2018.07.052. View

Wang X, Zhang Y, Hou W, Wang Y, Zheng J, Li J . Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study. Chin J Integr Med. 2019; 25(11):812-819. DOI: 10.1007/s11655-019-3168-6. View

Farge D, Durant C, Villiers S, Long A, Mahr A, Marty M . Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res. 2010; 125 Suppl 2:S108-16. DOI: 10.1016/S0049-3848(10)70027-X. View

Wang S, Long S, Wu W . Application of Traditional Chinese Medicines as Personalized Therapy in Human Cancers. Am J Chin Med. 2018; 46(5):953-970. DOI: 10.1142/S0192415X18500507. View

Yu S, Wang S, Huang S, Wang W, Wei Z, Ding Y . Radix et Rhizoma Ginseng chemoprevents both initiation and promotion of cutaneous carcinoma by enhancing cell-mediated immunity and maintaining redox homeostasis. J Ginseng Res. 2020; 44(4):580-592. PMC: 7322735. DOI: 10.1016/j.jgr.2019.05.004. View

Ahmad A, Raish M, Ganaie M, Ahmad S, Mohsin K, Al-Jenoobi F . Hepatoprotective effect of Commiphora myrrha against d-GalN/LPS-induced hepatic injury in a rat model through attenuation of pro inflammatory cytokines and related genes. Pharm Biol. 2015; 53(12):1759-67. DOI: 10.3109/13880209.2015.1005754. View

10.

Wang W, Wang H, Wang C, Gou S, Chen Z, Guo J . Treatment with Huisheng oral solution inhibits the development of pulmonary thromboembolism and metastasis in mice with Lewis lung carcinoma. Oncol Lett. 2013; 7(1):87-94. PMC: 3861555. DOI: 10.3892/ol.2013.1661. View

11.

Guo Y, Shen D, Yang H . [Analysis on composition regularity of carthami flos-containing traditional Chinese medicines]. Zhongguo Zhong Yao Za Zhi. 2014; 39(11):2144-8. View

12.

Lee J, Lee D, Kim Y, Kim H . 5-Lipoxygenase Inhibition of the Fructus of Foeniculum vulgare and Its Constituents. Biomol Ther (Seoul). 2013; 20(1):113-7. PMC: 3792194. DOI: 10.4062/biomolther.2012.20.1.113. View

13.

Han Y, Wang H, Xu W, Cao B, Han L, Jia L . Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement Ther Med. 2016; 24:81-9. DOI: 10.1016/j.ctim.2015.12.008. View

14.

Hou C, Jiang F, Ma H, Zhu Q, Wang Z, Zhao B . Prognostic role of preoperative platelet, fibrinogen, and D-dimer levels in patients with non-small cell lung cancer: A multicenter prospective study. Thorac Cancer. 2019; 10(2):304-311. PMC: 6360242. DOI: 10.1111/1759-7714.12956. View

15.

Nierodzik M, Karpatkin S . Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006; 10(5):355-62. DOI: 10.1016/j.ccr.2006.10.002. View

16.

Wang L, Jia K, Li F, Zhang C, Feng G, Du J . Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study. Front Pharmacol. 2021; 12:719802. PMC: 8443780. DOI: 10.3389/fphar.2021.719802. View

17.

Chen Z, Liu M, Xie K, Chen H, Wang J, Liu X . Huisheng Oral Solution exerts anti-tumor effects by downregulating tissue factor and inhibiting the expression of metastasis-related factors, CD44, MMP2, and VEGF. Transl Cancer Res. 2022; 8(7):2602-2612. PMC: 8798869. DOI: 10.21037/tcr.2019.10.25. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Ohtaki Y, Shimizu K, Kaira K, Nagashima T, Obayashi K, Nakazawa S . Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer. Surg Today. 2016; 46(10):1196-208. DOI: 10.1007/s00595-015-1301-5. View

20.

Yu N, Xiong Y, Wang C . Bu-Zhong-Yi-Qi Decoction, the Water Extract of Chinese Traditional Herbal Medicine, Enhances Cisplatin Cytotoxicity in A549/DDP Cells through Induction of Apoptosis and Autophagy. Biomed Res Int. 2017; 2017:3692797. PMC: 5244006. DOI: 10.1155/2017/3692797. View